Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations

Published:2023-09-04 Issue:4 Volume:26 Page:
ISSN:1792-0981
Container-title:Experimental and Therapeutic Medicine
language:
Short-container-title:Exp Ther Med

Author:

Li Junzhe¹,Wu Xiayu²,Ji Xiang-Bo³,He Changhao³,Xu Shijie³,Xu Xianhua²

Affiliation:

1. Department of Thoracic Surgery, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan 570312, P.R. China

2. Department of Pathology, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan 570312, P.R. China

3. Department of Medical Research Center, Affiliated Cancer Hospital of Hainan Medical University, Haikou, Hainan 570312, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Immunology and Microbiology (miscellaneous),General Medicine

Reference40 articles.

1. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy;Osmani;Semin Cancer Biol,2018

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3